<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367559</url>
  </required_header>
  <id_info>
    <org_study_id>VX-2017.01</org_study_id>
    <nct_id>NCT03367559</nct_id>
  </id_info>
  <brief_title>Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam</brief_title>
  <official_title>An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bharat Biotech International Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live&#xD;
      attenuated oral rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks&#xD;
      and 8 weeks in Vietnam.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live attenuated rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks and 8 weeks in Vietnam</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and rate of the AEs within 30 minutes after vaccination</measure>
    <time_frame>30 minutes after vaccination</time_frame>
    <description>Frequency and rate of the adverse effects and severity of immediate adverse events (Local and General) within 30 minutes after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and rate of the AEs within 7 days after vaccination</measure>
    <time_frame>for 7 days after each vaccination</time_frame>
    <description>Frequency and rate of adverse effects and severity of solicited adverse events (Local and General) within 7 days after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and rate of the AEs during 28 days after vaccination</measure>
    <time_frame>for 28 days after vaccination</time_frame>
    <description>Frequency and rate of adverse effects and severity of unsolicited adverse events (Local and General) during 28 days after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and rate of the SAEs during 28 days after vaccination</measure>
    <time_frame>for 28 days after vaccination</time_frame>
    <description>Frequency and rate of adverse effects and severity of Serious Adverse Events (Local and General) during 28 days after each vaccination</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Rotavirus Infections</condition>
  <arm_group>
    <arm_group_label>Rotavirus Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ROTAVAC®</intervention_name>
    <description>Rotavac® is in frozen form and is thawed till fully liquid prior to administration.</description>
    <arm_group_label>Rotavirus Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy infants as established by medical history and clinical examination before&#xD;
             entering the study.&#xD;
&#xD;
          -  Age: 6-8 weeks&#xD;
&#xD;
          -  Weight ≥ 2.5kg at birth.&#xD;
&#xD;
          -  Infants received EPI vaccines at birth (i.e., OPV, BCG and/or Hep B)&#xD;
&#xD;
          -  Parental ability and willingness to provide informed consent.&#xD;
&#xD;
          -  Parent who intends to remain in the area with the participant during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment&#xD;
             (temporary exclusion).&#xD;
&#xD;
          -  Presence of fever (temperature ≥37.5oC) or hypothermia (temperature ≤35.5oC) on the&#xD;
             day of enrollment (temporary exclusion).&#xD;
&#xD;
          -  Concurrent participation in another clinical trial.&#xD;
&#xD;
          -  Presence of significant malnutrition or any systemic disorder (cardiovascular,&#xD;
             pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological,&#xD;
             dermatological, neurological, cancer or autoimmune disease) as determined by medical&#xD;
             history and/or physical examination which would compromise the infant's health or is&#xD;
             likely to result in non-conformance to the protocol.&#xD;
&#xD;
          -  History of congenital abdominal disorders, intussusception, abdominal surgery&#xD;
&#xD;
          -  Known or suspected impairment of immunological function based on medical history and&#xD;
             physical examination.&#xD;
&#xD;
          -  Prior receipt of rotavirus vaccine.&#xD;
&#xD;
          -  A known sensitivity or allergy to any components of the study medication.&#xD;
&#xD;
          -  Major congenital or genetic defect.&#xD;
&#xD;
          -  Participant's parents not able, available or willing to accept active follow-up by the&#xD;
             study staff.&#xD;
&#xD;
          -  Has received any immunoglobulin therapy and/or blood products since birth or planned&#xD;
             administration during the study period.&#xD;
&#xD;
          -  History of chronic administration (defined as more than 14 days) of immunosuppressants&#xD;
             including corticosteroids. Infants on inhaled or topical steroids may be permitted to&#xD;
             participate in the study.&#xD;
&#xD;
          -  History of any neurologic disorders or seizures.&#xD;
&#xD;
          -  Any medical condition in the parents/infants that, in the judgment of the&#xD;
             investigator, would interfere with or serves as a contraindication to protocol&#xD;
             adherence or a participant's parent's/legally acceptable representative's ability to&#xD;
             give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thai Binh Health Center</name>
      <address>
        <city>Thái Bình</city>
        <zip>410000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vietnam Military Medical University</investigator_affiliation>
    <investigator_full_name>Pham Ngoc Hung, MD PhD Assoc</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rotavirus</keyword>
  <keyword>ROTAVAC</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Vietnam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

